GlassScriptPhysician profile
Melissa Baldwin
NPI 1487246278
$7,909.04
in general payments reported to CMS, 2019-2025
27 companies · $2,675 in 2025
The $2,675 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $1,052 · 2023: $1,908 · 2024: $2,121 · 2025: $2,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,581 · Consulting Fee: $64.23 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,581.48 |
| Consulting Fee | $64.23 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,351.80 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $949.17 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $878.61 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $847.92 | 2021-2025 | |
| Csl Behring | $748.77 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $650.86 | 2021-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $440.14 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $325.30 | 2025 | Neffy |
| Genentech USA, INC. | $298.61 | 2023-2025 | Xolair |
| Leo Pharma INC. | $239.60 | 2022-2025 | Adbry, Anzupgo |
| Pharming Healthcare, INC. | $194.23 | 2023-2025 | Ruconest |
| Amgen INC. | $165.57 | 2022-2025 | Tezspire |
| Phadia US INC. | $150.30 | 2024 | Immunocap |
| Biocryst US Sales Co., LLC | $141.20 | 2024-2025 | Orladeyo |
| Kaleo, INC. | $92.98 | 2022-2023 | Auvi-Q |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $80.48 | 2024-2025 | Ebglyss |
| Pfizer INC. | $71.13 | 2023-2025 | |
| Adma Biomanufacturing LLC | $64.23 | 2024-2025 | |
| Blueprint Medicines Corporation | $48.28 | 2024 | Ayvakit |
| Paratek Pharmaceuticals, INC. | $36.79 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $34.49 | 2024 | Ryaltris |
| Verona Pharma, INC. | $21.58 | 2025 | Ohtuvayre |
| Seqirus USA INC | $17.57 | 2024 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $15.76 | 2023 | |
| Alk-Abello, INC | $15.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.54 | 2024 | Eohilia |
| Greer Laboratories, INC. | $13.61 | 2024 | Palforzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.